Skip to content

HEPION PHARMACEUTICALS, INC.: 10-Q filed 2018-08-14

What HEPION PHARMACEUTICALS, INC. reported in its quarterly report filed 2018-08-14 (fiscal Q2 2018): 27 published measures, 63 facts as tagged in accession 0001104659-18-052012.

This filing

Form
10-Q (quarterly report)
Filed
2018-08-14
Fiscal period
fiscal Q2 2018
Accession
0001104659-18-052012 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HEPION PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-06-307,975,241USD
At 2017-12-3111,252,900USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-06-308,726,758USD
At 2017-12-317,549,743USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-06-30-751,517USD
At 2017-12-313,703,157USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-4,029,075USD91
2018-01-01 to 2018-06-30-6,719,563USD181
2017-04-01 to 2017-06-302,049,960USD91
2017-01-01 to 2017-06-30-5,568,666USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-7,009,701USD181
2017-01-01 to 2017-06-30-9,464,217USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-06-302,425USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-06-303,635,140USD181
2017-01-01 to 2017-06-3011,897,669USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-06-30900USD181
2017-01-01 to 2017-06-30-2,425USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-06-30-73,734,200USD
At 2017-12-31-67,014,637USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-536,000USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-06-3041,716USD
At 2017-12-3156,595USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-06-30370,151USD181
2017-01-01 to 2017-06-30827,701USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-3,884,397USD91
2018-01-01 to 2018-06-30-7,746,008USD181
2017-04-01 to 2017-06-30-5,216,316USD91
2017-01-01 to 2017-06-30-10,124,495USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-06-302,741,062USD
At 2017-12-316,062,092USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2018-04-01 to 2018-06-30231,948USD91
2018-01-01 to 2018-06-30231,948USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-06-304,999,635USD
At 2017-12-312,603,581USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-06-302,079,313USD
At 2017-12-311,556,883USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2018-06-301,870,924USD
At 2017-12-311,870,924USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-04-01 to 2018-06-302,122,898USD91
2018-01-01 to 2018-06-304,383,602USD181
2017-04-01 to 2017-06-303,259,983USD91
2017-01-01 to 2017-06-306,204,635USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-06-3010,692,174shares
At 2017-12-319,792,497shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-06-30920,322USD
At 2017-12-311,046,698USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-4,029,075USD91
2018-01-01 to 2018-06-30-7,255,563USD181
2017-04-01 to 2017-06-302,049,960USD91
2017-01-01 to 2017-06-30-5,568,666USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-4,029,075USD91
2018-01-01 to 2018-06-30-6,719,563USD181
2017-04-01 to 2017-06-302,049,960USD91
2017-01-01 to 2017-06-30-5,568,666USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-301,761,499USD91
2018-01-01 to 2018-06-303,362,406USD181
2017-04-01 to 2017-06-301,956,333USD91
2017-01-01 to 2017-06-303,919,860USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2018-01-01 to 2018-06-309,505USD181
2017-01-01 to 2017-06-3014,854USD181

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-536,000USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-01-01 to 2018-06-301,635,140USD181
2017-01-01 to 2017-06-3013,563,159USD181

Inspect the source

Entity
HEPION PHARMACEUTICALS, INC. / CIK 0001583771
Captured
2026-09-20T09:23:01.444Z
SEC response SHA-256
8713b65a28b6abe1fe9df431214197b2d073688f1082552d43175ea3504e60ff

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001583771.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))